MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial
(2022)
Journal Article
Rodriguez, D., Calmon, R., Aliaga, E. S., Warren, D., Warmuth-Metz, M., Jones, C., Mackay, A., Varlet, P., Le Deley, M. C., Hargrave, D., Cañete, A., Massimino, M., Azizi, A. A., Saran, F., Zahlmann, G., Garcia, J., Vassal, G., Grill, J., Peet, A., Dineen, R. A., …Jaspan, T. (2022). MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial. Radiology, 304(1), 174-182. https://doi.org/10.1148/radiol.211464
Background Diffuse midline gliomas (DMG) are characterized by a high incidence of H3 K27 mutations and poorer outcome. The HERBY trial has provided one of the largest cohorts of pediatric DMGs with available radiologic, histologic-genotypic, and surv... Read More about MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial.